

Association between APOE genotypes and Metabolic Syndrome in a Middle Aged and Elderly Urban Indian Population

Shilna Azhuvalappil^{1,2}, Raghav Prasad¹, Pravin Sahadevan¹, Priya Chatterjee¹, Hitesh Pradhan¹, Pooja Rai¹, Anant Gupta^{1, 3},
Reddy Peera Kommaddi¹, Thomas G. Issac¹, Jonas S. Sundarakumar^{1*}

¹ Centre for Brain Research, Indian Institute of Science, Bangalore 560012, India

² Indian Institute of Science Education and Research (IISER), Kolkata 741246, India

³ Manipal Academy of Higher Education, Manipal, India.

*Corresponding author

Jonas S. Sundarakumar
Centre for Brain Research
Indian Institute of Science
C.V. Raman Avenue
Bangalore – 560012, India.
Email: sjonas@cbr-iisc.ac.in

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background: This study examines the association between apolipoprotein E (APOE) genotypes and metabolic syndrome (MetS) in an older urban population in South India, as part of the Tata Longitudinal Study on Aging.

Methods: A total of 618 participants aged 45 and above were analyzed cross-sectionally for the association between APOE carrier status and MetS (based on both NCEP ATP III and Consensus criteria).

Results: Despite the high prevalence of MetS observed in this cohort (51.62% by NCEP-ATP III and 61.33% by Consensus criteria), multivariable logistic regression revealed no significant association between APOE genotypes and MetS under both criteria. However, specific associations were noted in age and sex-stratified analyses; notably, E2 carriers under 60 showed 0.42-fold decreased odds (95%CI:0.20,0.89, p-value-0.023) for an increased waist circumference, and E4 carriers above 60 were at 1.85 times increased odds (95% CI:1.04,3.28, p-value<0.05) for decreased HDL.

Conclusion: These findings suggest that while APOE genotypes influence certain metabolic parameters, their impact on MetS may be limited in this urban setting, possibly overshadowed by environmental factors and lifestyle influences which was highlighted by the differences seen in its sister rural cohort.

Keywords: Apolipoprotein E (APOE), Metabolic Syndrome, Aging, Cardiovascular Diseases, Lipid Metabolism

Introduction

Metabolic syndrome (MetS) is the concurrent presence of elevated blood pressure, hyperglycemia, dyslipidemia, and abdominal obesity (1). MetS has been associated with a two-fold increased risk for cardiovascular disease (CVD) and a 1.5-fold increased risk of all-cause mortality (2).

APOE plays a crucial role in managing various blood lipids, affecting the levels of triglycerides (TG), and lipoprotein particles in the plasma (3). The APOE gene has three common alleles— $\epsilon 2$, $\epsilon 3$, and $\epsilon 4$ —which produce three major isoforms: E2, E3, and E4. These alleles result in three homozygous genotypes (E2/2, E3/3, E4/4) and three heterozygous genotypes (E2/3, E2/4, E3/4). Each allele has a distinct binding affinity for lipoprotein receptors, which significantly impacts lipid transport, thus contributing to differing risks for MetS (4). Studies in diverse populations have noted associations between the APOE E4 allele and metabolic syndrome. However, data from the Indian populations on this relationship are scarce.

Our study examines the link between APOE genotypes and metabolic syndrome (MetS) and its components in middle-aged and older adults from urban India. We then compare these findings with those from a harmonized rural sister-cohort (5). Furthermore, considering previous findings that the effects of APOE vary with age and sex, particularly in factors like hypertension (6,7), we will also employ an age and sex-stratified approach. We hypothesize that APOE carrier status is associated with MetS.

Methods

The present study is a cross-sectional analysis of data from an ongoing aging cohort study in urban southern India named the Tata Longitudinal Study on Aging (TLSA), which recruits participants aged 45+ years from the city of Bangalore, India.

The analytical sample for this study (n=618) includes participants who had undergone their baseline clinical and biochemical assessments between 2015, June, and 2023, December and had complete data on the variables included in this study. Individuals diagnosed with dementia, severe medical or psychiatric illnesses, and sensory or motor impairments that could affect the study evaluations were excluded. Further, participants with APOE $\epsilon 2/\epsilon 4$ genotype were excluded due to the potentially contrasting effects of $\epsilon 2$ and $\epsilon 4$ alleles on lipid levels.

Clinical and anthropometric measures were collected using a structured clinical questionnaire that gathered demographic characteristics, clinical history of comorbidities, and data on physical inactivity, tobacco, and alcohol consumption.

Anthropometric data, including waist circumference (WC) and blood pressure, were measured by trained nurses. Biochemical investigations involved fasting peripheral venous blood samples analyzed by an accredited lab for glucose, triglycerides, LDL, and HDL.

Metabolic syndrome (MetS) was defined according to the NCEP ATP III (8) and Consensus criteria (9). APOE genotyping methods are detailed elsewhere (10). Participants were classified into E2 carriers (with either $\epsilon 2/\epsilon 2$ or $\epsilon 2/\epsilon 3$ genotype), E4 carriers (with either $\epsilon 4/\epsilon 4$ or $\epsilon 3/\epsilon 4$ genotype), and E3 homozygous ($\epsilon 3/\epsilon 3$ genotype) individuals, who served as the reference group in the logistic regression model.

Participant characteristics were summarized as frequencies and percentages for categorical variables and means with standard deviations for continuous ones. We tested differences between variables and metabolic syndrome (MetS), defined by NCEP ATP III criteria, using independent two-sample t-tests for continuous variables and chi-square tests for categorical variables. Multivariable binary logistic regression assessed the association between APOE genotypes and MetS and its components, adjusting for covariates. A p-value of <0.05 was deemed statistically significant. All analyses were conducted using Stata version 18.0.

Results

Out of the 618 study participants, 319 (51.62%) were diagnosed with MetS, respectively (as per the NCEP ATP-III criteria). There were significant differences in the distribution of age, sex, education, diabetes mellitus, hypertension, cardiac illness, high blood pressure, hyperglycemia, hypertriglyceridemia, low HDL-C, body mass index, and high waist circumference between the MetS and no MetS group (**Table 1**). There was no statistically significant difference in the distribution of APOE genotypes by MetS in both criteria (**Table 1 & Supplementary Table 1**).

Multivariable logistic regression models showed no significant association between APOE genotypes and metabolic syndrome per the NCEP ATP III or the Consensus criteria. Among the individual components of MetS, we only found that E2 carriers exhibited 0.42-fold decreased odds for high waist circumferences (95% CI: 0.20,0.89, p-value- 0.023) according to the consensus criteria. (**Table 2**).

On stratifying the population by sex, we again found no significant association between APOE and MetS for either criterion or its components in both sexes (**Supplementary Table 2**).

Upon age stratification (<60 and ≥ 60) there was no association seen between MetS and APOE in either group. In the group < 60 years we found that E2 carriers had decreased odds for high WC (OR: 0.18, 95% CI: 0.04,0.88, p-value < 0.05). In the age group of ≥ 60 years for E4 carriers we found that they had 1.85 times increased odds (95% CI: 1.04,3.28, p-value < 0.05) for decreased HDL (**Supplementary Table 3**).

Discussion

Our study of urban Indians aged 45 and older found a high prevalence of metabolic syndrome: 51.62% by NCEP-ATP III criteria and 61.33% by Consensus criteria. Whereas the prevalence in the rural sister cohort was 38.5% and 46.5% respectively. This compares to a national prevalence of 41-50% for a similar age group reported in a recent meta-analysis (11). Even among the participants who did not meet the criteria for metabolic syndrome, there was a high prevalence of its components, ranging from 16% to 54%.

However, we found no significant association between APOE and MetS. Prior studies from various populations have revealed conflicting findings, reporting a significant association (12–14), while others from India (15) and China (1) have reported a lack of association. Such variations in the findings could be attributed to the differences in the demographics of the populations examined, different inclusion and exclusion criteria, and the use of different criteria for diagnosis of MetS.

Recent findings from the SANSCOG study revealed a sex-specific association between APOE and MetS, wherein the rural females had increased odds for MetS, hypertriglyceridemia, and low HDL (10). In contrast, this study found no significant association with most of the MetS components, which is also contrary to the existing literature where APOE is significantly associated with lipid, glycemic (16), and blood pressure parameters (17). However, when we age-stratified, we saw that participants aged 60 years and above had increased odds of low HDL. Previous studies have indicated that the interaction of APOE with components of MetS changes with age (7). Accordingly, we found a significant association between high WC (consensus criteria) and APOE genotype in the total population which on age stratification was only present in the <60 age group.

The discordance of our results with our sister study and the overall contrasting evidence for APOE polymorphisms and MetS could be due to varying exposure to environmental risk factors, which, in turn, could have diminished the genetic influence of APOE on MetS. Further, differential healthcare access and treatment of the metabolic risk factors could potentially confound this association. Finally, since there is tremendous genetic diversity in the Indian population, it is possible that the lack of association between the APOE allele and MetS could be unique to our study population. Significant differences in APOE E4 allele frequency have been reported in the Indian population compared to other populations (18). The role of APOE has been most widely studied as a risk factor for dementia and cognitive performance and differences in the association between APOE allele status and dementia/cognitive performance across ancestries and ethnicities have been reported (19). Linkage disequilibrium, allele frequencies, and genetic architecture of a population could modulate the relationship between genetic effects and diseases (20).

The limitations of our study include its small sample size, which may hinder the generalizability of our findings. Additionally, the use of convenience sampling might not provide a sample that is representative of the broader urban Indian population. The cross-sectional design of the study also prevents us from establishing causality between APOE genotypes and MetS. Furthermore, we did not consider several other genetic factors that could influence the MetS burden.

To the best of our knowledge, this is the first and most comprehensive study from India to assess the association between APOE and MetS in the middle-aged and older urban population with an objective diagnosis of all MetS components. Also, this paper is the first of its kind to compare APOE polymorphisms between rural and urban populations from two harmonized studies which are within a small geographical distance thus making the comparison reliable. We also looked at sex-specific and age-specific associations and gathered important insights that align with the limited previous literature on the same.

In conclusion, environmental factors in the urban population could potentially outweigh the genetic predisposition in determining health risks, therefore, highlighting the requirement of lifestyle modification in managing cardio-metabolic diseases in this population.

Ethics Approval Statement:

All participants provided written informed consent before their involvement in the study. The study protocol received approval from the Institutional Review Board at the Institute. All experiments conducted adhered to the appropriate guidelines and regulations. The Institutional Ethical Clearance number provided for this study is CBR/42/IEC/2022-23.

Conflicts of interest: All authors declare no conflicts of interest.

Author Contributions:

Conception: JSS, SA; Acquisition, Analysis, or Interpretation of data: JSS, TGI, RPK, PR, SA, PS, HP, AG; Drafting the work or revising: SA, PC, RP, JSS, TGI; Final approval of the manuscript: JSS, TGI, RPK, PC, RP.

Funding: CBR-TLSA is funded by Tata Trusts.

Acknowledgments: We are grateful to the volunteers who participated in the CBR-TLSA study. We acknowledge all members of the CBR-TLSA study team for their valuable contributions to various aspects of the CBR-TLSA study.

References:

1. Jeenduang N, Porntadavity S, Nuinoon M, Horpet D, Thepkwan N, Thaworn P, et al. Studies of the CETP TaqIB and ApoE Polymorphisms in Southern Thai Subjects with the Metabolic Syndrome. *Biochemical Genetics*. 2015 Aug 29;53(7–8):184–99.
2. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. *J Am Coll Cardiol*. 2010 Sep 28;56(14):1113–32.
3. Mahley RW, Jr SCR. Apolipoprotein E: Far More Than a Lipid Transport Protein. *Annual Review of Genomics and Human Genetics*. 2000 Sep 1;1(Volume 1, 2000):507–37.
4. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. *Arteriosclerosis: An Official Journal of the American Heart Association, Inc.* 1988 Jan;8(1):1–21.
5. Ravindranath V, SANSCOG Study Team. Srinivasapura Aging, Neuro Senescence and COGnition (SANSCOG) study: Study protocol. *Alzheimer’s & Dementia*. 2023 Jun;19(6):2450–9.
6. Léa Correa Leite M, Lima-Costa MF, Moriguchi EH. Age-related trends of blood pressure levels by apolipoprotein E genotype: the Bambui Cohort Study of Ageing (1997-2008). *Hypertens Res*. 2013 Mar;36(3):270–6.
7. Belloy ME, Andrews SJ, Le Guen Y, Cuccaro M, Farrer LA, Napolioni V, et al. APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry. *JAMA Neurology*. 2023 Dec 1;80(12):1284–94.
8. Denke MA, Pasternak RC. Defining and treating the metabolic syndrome: A primer from the Adult Treatment Panel III. *Curr Treat Options Cardio Med*. 2001 Jul 1;3(4):251–3.
9. Sundarakumar JS, Stezin A, Menesgere AL, Ravindranath V. Rural-urban and gender differences in metabolic syndrome in the aging population from southern India: Two parallel, prospective cohort studies. *eClinicalMedicine*. 2022 May;47:101395.
10. Azhuvalappil S, Prasad R, Sahadevan P, Pradhan H, Rai P, Sundarakumar JS. Sex-specific differences in the association between APOE genotype and metabolic syndrome among middle-aged and older rural Indians. *Metabolism Open*. 2024 Apr 9;100281.
11. Krishnamoorthy Y, Rajaa S, Murali S, Rehman T, Sahoo J, Kar SS. Prevalence of metabolic syndrome among adult population in India: A systematic review and meta-analysis. *PLoS One*. 2020 Oct 19;15(10):e0240971.
12. Olivieri O, Martinelli N, Bassi A, Trabetti E, Girelli D, Pizzolo F, et al. ApoE ε2/ε3/ε4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome. *Clin ExperMed*. 2007 Dec 1;7(4):164–72.
13. Association between APOE polymorphism and metabolic syndrome in Uyghur ethnic men | *BMJ Open* [Internet]. [cited 2024 Apr 29]. Available from: <https://bmjopen.bmj.com/content/6/1/e010049>
14. Tao MH, Liu JW, LaMonte MJ, Liu J, Wang L, He Y, et al. Different associations of apolipoprotein E polymorphism with metabolic syndrome by sex in an elderly Chinese population. *Metabolism*. 2011 Oct;60(10):1488–96.
15. Ranjith N, Pegoraro RJ, Rom L. Lipid Profiles and Associated Gene Polymorphisms in Young Asian Indian Patients With Acute Myocardial Infarction and the Metabolic Syndrome. *Metabolic Syndrome and Related Disorders*. 2009 Dec;7(6):571–8.
16. El-Lebedy D, Raslan HM, Mohammed AM. Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease. *Cardiovascular Diabetology*. 2016 Jan 22;15(1):12.
17. Shi J, Liu Y, Liu Y, Li Y, Qiu S, Bai Y, et al. Association between *ApoE* polymorphism and hypertension: A meta-analysis of 28 studies including 5898 cases and 7518 controls. *Gene*. 2018 Oct 30;675:197–207.
18. Jolly B, Scaria V. Alzheimer’s Disease-Associated APOE ε4 Frequencies in Indian Population Genomes May Suggest Implications in Lecanemab Treatment. *J Prev Alzheimers Dis*. 2024 Mar 1;11(2):525–6.
19. Naslavsky MS, Suemoto CK, Brito LA, Scliar MO, Ferretti-Rebustini RE, Rodriguez RD, et al. Global and local ancestry modulate APOE association with Alzheimer’s neuropathology and cognitive outcomes in an admixed sample. *Mol Psychiatry*. 2022 Nov;27(11):4800–8.
20. Martin AR, Gignoux CR, Walters RK, Wojcik GL, Neale BM, Gravel S, et al. Human Demographic History Impacts Genetic Risk Prediction across Diverse Populations. *Am J Hum Genet*. 2017 Apr 6;100(4):635–49.

Table 1

Demographic, anthropometric, and plasma biochemical characteristics of the participants of rural cohort (MetS defined by NCEP ATP-III criteria)

Characteristics	MetS (n=319) (%)	No MetS (n=299) (%)	P-value
Age, mean (SD)	60.81 (8.61)	62.71 (10.13)	0.012
Sex			<0.001
Male	134 (42.01)	172 (57.53)	
Female	185 (57.99)	127 (42.47)	
Education			0.002
Illiterate	14 (4.39)	7 (2.34)	
Primary/Middle school	17 (5.33)	7 (2.34)	
High school/Diploma	78 (24.45)	48 (16.05)	
Graduate/Postgraduate	210 (65.83)	237 (79.26)	
Marital status			0.326
Living without a partner	47 (14.73)	36 (12.04)	
Living with a partner	272 (85.27)	263 (87.96)	
Tobacco usage			0.368
No	304 (95.30)	280 (93.65)	
Yes	15 (4.70)	19 (6.35)	
Alcohol usage			0.108
No	262 (82.13)	230 (76.92)	
Yes	57 (17.87)	69 (23.08)	
Diabetes mellitus			<0.001
Yes	147 (46.08)	55 (18.39)	
No	172 (53.92)	244 (81.61)	
Hypertension			<0.001
Yes	252 (79.00)	157 (52.51)	
No	67 (21.00)	142 (47.49)	
Cardiac illness			<0.001
Yes	23 (7.21)	24 (8.03)	
No	296 (92.76)	275 (91.97)	
Hypertriglyceridemia			<0.001
Yes	202 (63.32)	50 (16.72)	
No	117 (36.68)	249 (83.28)	
Low HDL-C			<0.001
Yes	236 (73.98)	74 (24.75)	
No	83 (26.02)	225 (75.25)	
Asian body mass index			<0.001
Underweight	0 (0.00)	4 (1.35)	
Normal	28 (8.89)	73 (24.66)	
Overweight	29 (9.21)	63 (21.28)	
Obesity	258 (81.90)	156 (52.70)	
High waist circumference (NCEP ATP-III criteria)			<0.001
Yes	247 (77.43)	86 (28.76)	
No	72 (22.57)	213 (71.24)	
High waist circumference (Consensus criteria)			<0.001
Yes	297 (93.10)	227 (75.92)	
No	22 (6.90)	72 (24.08)	
APOE genotype			0.376
□2/ □2	1 (0.31)	0 (0.00)	
□2/ □3	18 (5.64)	28 (9.36)	
□3/ □3	246 (77.12)	218 (72.91)	
□3/ □4	52 (16.30)	51 (17.06)	
□4/ □4	2 (0.63)	2 (0.67)	
APOE carriers			0.249
E2 carriers	19 (5.96)	28 (9.36)	
E3 homozygous	246 (77.12)	218 (72.91)	
E4 carriers	54 (16.93)	53 (17.73)	

Note. MetS Metabolic Syndrome; HDL-C High Density Lipoprotein Cholesterol; APOE Apolipoprotein E

Table 2

Association between ApoE genotype and individual component of MetS

Outcome	APOE3	APOE2	APOE4
High blood pressure ^g	1.00 (Reference)	0.71 (0.35-1.44)	0.81 (0.50-1.31)
Hyperglycemia ^g	1.00 (Reference)	1.23 (0.63-2.40)	1.08 (0.69- 1.70)
Hypertriglyceridemia ^g	1.00 (Reference)	1.34 (0.69-2.59)	1.05 (0.66-1.66)
Low HDL-C ^g	1.00 (Reference)	0.84 (0.43-1.63)	1.43 (0.91-2.24)
High waist circumference (NCEP ATP-III criteria) ^g	1.00 (Reference)	0.61 (0.30-1.23)	0.89 (0.54-1.45)
High waist circumference (Consensus criteria) ^g	1.00 (Reference)	0.42 (0.20-0.89) *	0.83 (0.45-1.54)
Mets (NCEP ATP-III criteria) ^f	1.00 (Reference)	0.68 (0.36-1.29)	0.92 (0.59-1.42)
Mets (Consensus criteria) ^f	1.00 (Reference)	0.79 (0.43-1.48)	1.15 (0.73-1.80)

Note. MetS Metabolic Syndrome; HDL-C High Density Lipoprotein Cholesterol, APOE Apolipoprotein E
*P-value<0.05
^f The logistic regression model adjusted for age, education, marital status, physical activity, alcohol usage, tobacco usage and cardiac illness
^g Each component of Mets was adjusted for other components along with sex, age, marital status, physical activity, alcohol usage, tobacco usage and cardiac illness